SG3 Management’s Intellia Therapeutics NTLA Stock Holding History

SG3 Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,000	Closed	-$1.74M	–	1208
2021 Q3	$1.74M	Sell	13,000 -12,000	-48%	-$1.82M	0.05%	335
2021 Q2	$4.05M	Buy	25,000 +15,000	+150%	+$1.17M	0.14%	165
2021 Q1	$803K	Buy	+10,000	New	+$671K	0.02%	658

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

SG3 Management's NTLA Position: Q4 2021 in Review

SG3 Management sold out of Intellia Therapeutics (NTLA) in Q4 2021, closing a stake of 13,000 shares — an estimated $1.74M sold.

SG3 Management first reported a position in NTLA in Q1 2021 and held it in 3 quarters. The position peaked at $4.05M in Q2 2021. 371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

SG3 Management reported no remaining Intellia Therapeutics position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 13,000 Intellia Therapeutics shares in Q4 2021, an estimated $1.74M.
SG3 Management first reported a position in Intellia Therapeutics in Q1 2021 and held it in 3 quarters.
SG3 Management's Intellia Therapeutics position peaked at $4.05M in Q2 2021.
371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.